Star Health and Allied Insurance is reportedly in preliminary discussions with potential strategic investors over a possible majority stake sale, with Japanese insurance players among those said to have expressed interest. The development is being driven primarily by existing shareholders seeking an exit, particularly private-equity investor WestBridge, according to people familiar with the discussions.
No transaction has been agreed, and the talks remain at an early stage. Star Health’s recent meetings with Japanese institutional investors in Tokyo provide evidence of increased engagement with the country’s investment community, but the company’s regulatory filings explicitly state that those meetings do not establish negotiations for a strategic investment or partnership.
Key takeaways
- Star Health is reportedly exploring a potential majority stake sale to a strategic investor.
- The discussions are at a preliminary stage and could take time to result in a transaction.
- WestBridge is understood to be seeking an exit from Star Health after becoming a promoter of newly launched general insurer Kiwi General Insurance.
- Japanese insurance and asset-management groups have recently held meetings with Star Health in Tokyo.
- Star Health’s Q1 FY27 financial performance has improved sharply, potentially making the insurer more attractive to strategic investors.
- The company reported ₹4,287 crore in gross written premium and ₹550 crore in profit after tax for the quarter ended June 30, 2026.
- There is currently no confirmed buyer, transaction value or agreed stake.
What is happening at Star Health?
Star Health, India’s largest standalone health insurer, is at the centre of preliminary discussions over a possible strategic investment that could result in a majority stake changing hands.
The reported discussions are significant because the potential transaction is not simply a conventional fund-raising exercise. Instead, it appears to be connected to existing shareholders looking to monetise their holdings while potentially bringing a long-term strategic insurance investor into the company.
According to Moneycontrol, people familiar with the discussions said multiple investors have shown interest, including Japanese insurers. The sources described the negotiations as nascent, meaning there is no certainty that they will result in a completed transaction.
The distinction is important. Star Health has not announced a strategic investment, named a buyer or disclosed a transaction valuation. The company has also previously declined to comment on market speculation, while WestBridge had not responded to Moneycontrol’s queries at the time of publication.
For now, the story is therefore best understood as an early-stage strategic-sale process rather than a confirmed acquisition.
Why WestBridge is central to the story
WestBridge’s position is important because the investment firm is a major shareholder in Star Health through Safecrop Investments India LLP.
As of June 30, 2026, Safecrop held about 40.17% of Star Health, according to India Ratings. The Jhunjhunwala family held another 16.33%, meaning these two shareholder groups together controlled more than half of the company’s equity at that point.
The ownership structure gives a potential strategic transaction considerable scale. A buyer acquiring a majority position would need to navigate not only the existing promoter holdings but also India’s regulatory framework for insurance ownership and control.
WestBridge’s strategic position has also changed because of its involvement with Kiwi General Insurance.
Kiwi is a newly licensed general insurer backed by WestBridge and insurance-industry veterans. Moneycontrol reported that WestBridge holds roughly 70% of Kiwi, with co-founder Neelesh Garg holding the balance, and that Kiwi began operations in June 2026.
That creates an important strategic backdrop for Star Health.
WestBridge has historically been a major investor in Star Health, but its involvement in another insurance company changes the economics and regulatory considerations around its insurance portfolio. The firm’s potential exit from Star Health has therefore been linked by market sources to its newer position in Kiwi.
The Kiwi General Insurance connection
Kiwi General Insurance is not a side issue in the Star Health story. It helps explain why an existing shareholder could be considering a change in ownership.
WestBridge has been associated with Star Health for years and was among the investors that backed the insurer before its public listing. The investment firm subsequently became a significant shareholder in Kiwi, which entered India’s general insurance market after receiving regulatory approval.
The regulatory framework governing insurance ownership makes promoter relationships particularly important.
IRDAI’s current regulatory framework covers the registration, capital structure, transfer of shares and amalgamation of insurers. Any significant ownership transaction in an insurer therefore involves regulatory considerations beyond those associated with an ordinary listed-company share sale.
Earlier reporting also highlighted questions around WestBridge’s promoter interests in Star Health and Kiwi.
This does not mean that WestBridge is legally required to sell Star Health immediately, nor does it establish that a specific transaction is being mandated by IRDAI. Rather, the ownership structure provides a plausible strategic reason for WestBridge to evaluate its options.
That distinction matters because the current reported discussions remain unconfirmed.
Why Japanese investors are being watched
Japanese interest is one of the most notable aspects of the reported process.
Star Health disclosed meetings with Japanese institutional investors in Tokyo on September 28 and September 29, 2026.
On September 28, company representatives were scheduled to meet Sumitomo Mitsui DS Asset Management, Sumitomo Mitsui Trust Asset Management and Sparx Asset Management Japan.
On September 29, the meetings included Nomura Asset Management, Daiwa Asset Management and Tokio Marine Asset Management.
These meetings demonstrate that Star Health has been actively engaging Japanese investors. However, they do not by themselves demonstrate that any of these institutions is negotiating to buy the company.
The distinction becomes particularly important in the context of the reported strategic-investor discussions.
The exchange disclosures describe the meetings as analyst and institutional-investor engagements. They do not identify them as merger-and-acquisition negotiations.
Tokio Marine Asset Management’s presence is nevertheless noteworthy because Tokio Marine is an established insurance group with operations and interests in the Indian insurance market.
But it would be premature to conclude that Tokio Marine or any other Japanese institution named in the investor-meeting filings is the prospective buyer.
The reported deal process could involve other investors that have not been publicly identified.
Star Health’s financial performance has improved
The potential ownership discussions come at a particularly important point in Star Health’s operating cycle.
The insurer’s Q1 FY27 performance showed a significant improvement in underwriting profitability.
For the quarter ended June 30, 2026, Star Health reported gross written premium, or GWP, of ₹4,287 crore, representing 19% year-on-year growth on a reported 1/N basis.
Profit after tax increased 25% year-on-year to ₹550 crore under Ind AS accounting.
More importantly for a strategic insurance investor, the company’s underwriting result increased sharply to ₹111 crore from ₹16 crore in the corresponding quarter a year earlier.
Underwriting profit is important because it reflects the economics of the insurance business itself rather than relying primarily on investment income. An insurer can generate accounting profit from its investment portfolio even when its core underwriting operation is weak. A move into positive and stronger underwriting profitability therefore provides a different quality of earnings signal.
Star Health’s combined insurance service ratio also improved to 97% in Q1 FY27 from 98.7% a year earlier.
Fresh retail health gross written premium rose 37% year-on-year to ₹730 crore.
Star Health’s Q1 FY27 performance
| Metric | Q1 FY26 | Q1 FY27 | Change |
|---|---|---|---|
| Gross written premium | ₹3,597 crore* | ₹4,287 crore | +19% |
| Profit after tax | ₹438 crore | ₹550 crore | +25% |
| Underwriting result | ₹16 crore | ₹111 crore | Strong improvement |
| Fresh retail health GWP | — | ₹730 crore | +37% |
| Combined insurance service ratio | 98.7% | 97.0% | Improved |
*Reported comparative figure in the company’s investor presentation.
The financial improvement does not prove that a stake sale will happen. It does, however, provide a more favourable operating backdrop for shareholders evaluating strategic alternatives.
Why a strategic investor could be interested
A strategic investor can bring something different from a traditional financial investor.
A private-equity investor generally focuses on financial returns, operational improvement and an eventual exit. A strategic insurance group can potentially bring underwriting expertise, technology, distribution capabilities, reinsurance relationships, product-development experience and international knowledge.
For Star Health, the strategic value could be particularly relevant as India’s health-insurance market continues to expand.
Star Health already has significant scale in standalone health insurance. A strategic partner could potentially use that existing distribution and customer base as a platform for broader insurance products, digital distribution or operational improvements.
However, these are potential benefits rather than announced plans.
There is no confirmed strategic partner and no public agreement describing what a buyer would do after acquiring a stake.
What a majority investment would mean
A majority strategic investment would be more consequential than a simple secondary share sale.
If an investor acquires enough shares to obtain control, it could influence the board, management strategy, capital allocation and long-term business direction.
For an insurer, ownership also has a regulatory dimension. Changes in significant ownership and control are subject to regulatory requirements, and the buyer would need to satisfy the applicable criteria before completing a transaction.
The final structure could therefore take several forms.
One possibility is a strategic investor buying shares from existing shareholders, allowing those investors to exit while the company receives little or no new capital.
Another possibility is a combination of secondary purchases and fresh capital being injected into Star Health.
A third structure could involve multiple existing shareholders selling different portions of their holdings to one or more strategic investors.
At this stage, none of these structures has been confirmed.
What happens to the Jhunjhunwala family’s stake?
The Jhunjhunwala family remains another important shareholder group.
As of June 30, 2026, Rekha Jhunjhunwala held 3.04% of Star Health, while Sitara Partners LLP held 13.29%.
Together, those holdings represented 16.33% of the company, according to India Ratings.
The reported discussions could therefore involve more than WestBridge, although the available reporting specifically identifies WestBridge as the principal shareholder seeking an exit.
Whether other promoter or major shareholder groups participate in a future transaction remains uncertain.
The ownership structure could ultimately determine whether a buyer takes majority control, acquires a smaller strategic stake or negotiates with multiple shareholders.
The importance of India’s health-insurance market
The potential transaction also highlights the strategic importance of India’s health-insurance sector.
Health insurance is structurally different from many other financial-services businesses because scale, claims management, provider networks, pricing discipline and customer trust all influence long-term economics.
Star Health’s position as a standalone health insurer gives a strategic investor direct exposure to this segment rather than requiring it to build a health-insurance platform from scratch.
The company’s recent operating numbers suggest that the business is also moving in a more favourable direction after a difficult period.
Its Q1 FY27 investor presentation showed the combined insurance service ratio improving to 97%, while the underwriting result moved from ₹16 crore to ₹111 crore.
That improvement could make the company more attractive in strategic discussions because a prospective buyer would be assessing both the franchise and its future earnings potential.
Still, a single quarter does not establish a permanent turnaround.
Health insurers remain exposed to medical inflation, claims severity, pricing competition, regulatory changes and shifts in customer behaviour. Any strategic buyer would therefore need to evaluate the business across a much longer period.
What remains uncertain
Several important questions remain unanswered.
First, there is no confirmed buyer.
Although Japanese investors have held meetings with Star Health, the exchange disclosures do not establish that those institutions are negotiating a strategic investment.
Second, there is no disclosed valuation.
The potential transaction value will depend on the stake being sold, the price negotiated with a buyer and any premium attached to control.
Third, the final ownership structure is unclear.
WestBridge is the most prominent shareholder linked to the reported exit discussions, but it is not yet known whether other shareholders will sell alongside it.
Fourth, regulatory approval could influence the timetable and final structure.
Insurance transactions are subject to regulatory scrutiny, particularly when they involve changes in significant ownership or control.
Finally, the discussions could end without a deal.
Preliminary strategic-investor talks frequently involve multiple potential buyers before shareholders settle on a structure, and some processes do not result in a transaction.
What happens next?
The next meaningful development would be evidence that the discussions have moved beyond exploratory conversations.
That could take the form of a formal announcement, a regulatory filing concerning a significant share transfer, a board-approved transaction, or disclosure of a strategic investor.
Until then, investor meetings should not be interpreted as confirmation of a takeover.
For Star Health, the combination of improving underwriting performance and a potentially changing shareholder structure creates an interesting strategic moment. The company is simultaneously demonstrating stronger operating metrics while one of its major investors is reportedly evaluating an exit.
For potential buyers, the attraction is the scale of Star Health’s standalone health-insurance franchise. For existing shareholders, the question is whether a strategic transaction can unlock value while maintaining the company’s competitive position.
The Bigger Picture
The reported Star Health strategic-investor talks show how India’s insurance sector is entering a phase in which ownership, capital and operating expertise are becoming increasingly intertwined. WestBridge’s involvement in both Star Health and Kiwi General Insurance provides an important backdrop to the reported exit discussions, while Japanese institutional interest shows that India’s insurance market continues to attract international investors.
The timing is also significant. Star Health has emerged from a period of weaker underwriting performance with a much stronger Q1 FY27, including ₹111 crore of underwriting profit and ₹550 crore of reported profit after tax. That does not guarantee a transaction, but it gives shareholders a stronger operating story to present to prospective strategic investors.
Looking Ahead
The immediate focus will be on whether preliminary discussions develop into a formal transaction and whether any Japanese or other international insurance group emerges as a named buyer. Until there is a binding agreement or regulatory disclosure, the identity of the potential investor, transaction value and final stake should be treated as unresolved.
For Star Health, the strategic question extends beyond who owns the shares. A new strategic investor could influence the company’s next phase of product development, distribution, technology and capital deployment. The eventual outcome will depend on valuation, regulatory approvals, shareholder decisions and the strategic objectives of any incoming investor.
FAQs
Is Star Health being sold?
Star Health is reportedly in preliminary discussions with potential strategic investors over a possible majority stake sale. No completed sale or binding transaction has been announced.
Are Japanese insurers buying Star Health?
Japanese investors have held meetings with Star Health in Tokyo, but the company’s exchange disclosures do not establish that any of those institutions is negotiating a strategic investment. A specific Japanese buyer has not been confirmed.
Why is WestBridge considering an exit from Star Health?
WestBridge is a major shareholder in Star Health and is also the majority shareholder in Kiwi General Insurance. Its involvement with the newly launched insurer has been cited as an important factor behind the reported evaluation of an exit from Star Health.
How is Star Health performing financially?
For Q1 FY27, Star Health reported ₹4,287 crore in gross written premium, up 19% year-on-year, and ₹550 crore in profit after tax, up 25%. Its underwriting result improved to ₹111 crore from ₹16 crore a year earlier.
What could happen next?
The process could lead to a strategic stake sale, another ownership arrangement or no transaction at all. Any significant change in ownership would also have to satisfy applicable insurance and securities-market regulatory requirements.
Get the day’s top stories in your inbox
One concise email. No spam, unsubscribe anytime.
